Abstract

Background:Sepsis-induced acute lung injury (ALI) poses a significant therapeutic challenge due to the lack of effective treatments. Shionone (SHI), a compound known for its anti-inflammatory properties, was investigated for its potential to mitigate ALI by modulating macrophage polarization, a key process in the inflammatory response. The underlying mechanism was also explored. Methods:We established lipopolysaccharide (LPS)-induced models of ALI in mice and RAW264.7 cells. The protective effects of SHI were assessed in vivo using lung histopathology (hematoxylin and eosin [H&E] staining) and the lung wet-to-dry weight ratio. Cell viability was assessed using a Cell Counting Kit-8 (CCK-8) assay. The levels of inflammatory cytokines (interleukin-6 [IL-6], interleukin-1 beta [IL-1β], tumor necrosis factor-alpha [TNF-α], granulocyte-macrophage colony-stimulating factor [GM-CSF], Interleukin-10 [IL-10], transforming growth factor-beta 1 [TGF-β1]) and polarization markers (inducible nitric oxide synthase [iNOS], arginase-1 [Arg1]) were quantified by enzyme-linked immunosorbent assay [ELISA] and real-time quantitative PCR. The expression of key proteins in the high-mobility group box 1 (HMGB1)/nuclear factor κ B (NF-κB) pathway (HMGB1, toll-like receptor 4 [TLR4], myeloid differentiation primary response 88 [MyD88], NF-κB p65) was analyzed by western blot and immunofluorescence. The study used a small interfering RNA [siRNA] loss-of-function strategy to demonstrate that HMGB1 is a critical target of SHI.Results:SHI treatment significantly attenuated sepsis-induced ALI in mice, as evidenced by improved lung histology, lower lung injury scores, and reduced pulmonary edema. In both in vivo and in vitro models, SHI suppressed the production of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and the M1 macrophage marker iNOS, while enhancing the release of anti-inflammatory cytokines (GM-CSF, IL-10, TGF-β1) and the M2 marker Arg1. Mechanistically, SHI inhibited the activatio